What Qiming Venture Partners USA does

Qiming Venture Partners USA (Qiming US) is a US-based venture capital firm established in January 2017 as the US arm of China-based Qiming Venture Partners. The firm invests in early-stage healthcare companies in the United States and Europe, with two core verticals: Therapeutics (small molecule, antibody, and cell therapy approaches) and Digital Health (software, diagnostics, and health technology platforms). Portfolio companies receive capital alongside hands-on operational support, market diligence, and introductions into the broader Qiming network including the China market.

Since inception, Qiming US has raised $550 million across three successive funds and deployed into 30+ portfolio companies, achieving 11 M&A and IPO exits. The firm maintains three US offices — Cambridge (headquarters), Bellevue/Seattle (regional headquarters), and San Francisco — and positions itself as an entrepreneur-led team of investors and scientists with international operating experience. Qiming US does not charge portfolio companies for investment services; instead, the firm generates returns through equity investments realized via M&A exits, IPOs, and secondary transactions, while management fees and carried interest are sourced from limited partners. The differentiating value proposition is unencumbered access to Qiming's China network for cross-border diligence and operational support, paired with a hands-on approach from idea through regulatory approval and beyond.

Name

Qiming Venture Partners USA

Legal name

Qiming Venture Partners USA

Website

https://qimingvcusa.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

101–250 employees

Short description

Qiming Venture Partners USA is a venture capital firm founded in 2017 as the US arm of Qiming Venture Partners, investing in early-stage healthcare companies across therapeutics and digital health in the US and Europe with leveraged China market access.

Ownership category

akta.pro rank

Product category

Healthcare Venture Capital

NAICS

Miscellaneous Financial Investment Activities (523999), All Other Financial Investment Activities (52399)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

• Venture capital investment
• Healthcare venture capital
• Early-stage investing
• Therapeutics investment
• Digital health investing

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Investment Returns: Qiming US generates returns through equity investments in early-stage healthcare companies. Returns are realized through M&A exits, IPOs, and secondary transactions. The firm has achieved 11 M&A and IPO exits across its portfolio.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Qiming Venture Partners USA is a venture capital firm that makes early-stage equity investments in healthcare companies across the United States and Europe. The firm operates two core investment verticals — Therapeutics (antibody, small molecule, and cell therapies) and Digital Health (technology-enabled healthcare solutions) — and supplements capital with operational support, market diligence, and access to the broader Qiming China network.

Product overview

Qiming Venture Partners USA operates as a venture capital firm offering a unified investment platform with two core investment verticals: Therapeutics and Digital Health. The firm provides capital resources alongside human capital support services to healthcare entrepreneurs. The Therapeutics investment vertical focuses on next-generation therapies including antibody therapies, small molecule treatments, and cell therapies, while the Digital Health vertical targets technology-enabled healthcare solutions. Both verticals are supported by portfolio company support services including market diligence, deal flow facilitation, and operational support leveraging the firm's China market access and broader Qiming network. Since 2017, the firm has raised $550M across three funds, invested in 30+ portfolio companies, and achieved 11 M&A and IPO exits.

Differentiator

Problem solved

Functional benefit

Products and services

• Therapeutics Investment Early-stage venture capital equity investments in healthcare companies developing transformative therapeutic solutions, including antibody therapies, small molecule treatments, and cell therapy approaches. Targeted at founders and entrepreneurs building next-generation therapies that improve patient outcomes.
• Digital Health Investment Early-stage venture capital equity investments in digital health companies developing technology-enabled healthcare solutions, including software platforms, diagnostics, and health technology offerings. Targeted at entrepreneurs building technology-driven healthcare businesses.
• US-Europe Healthcare Fund Early-stage venture fund investing in healthcare opportunities across the United States and Europe, with cross-border access to the China market and broader Qiming network for deal sourcing and operational support. Raised $550M across three fund vintages since inception.

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Versant Ventures: Healthcare-dedicated venture firm with a similar stage-and-therapeutics focus; co-led the Dualitas Series A with Qiming US, indicating directly overlapping investment criteria and check sizes in early-stage biotech.
• Atlas Venture: Boston-based early-stage healthcare/therapeutics specialist; operates a comparable "build-from-scratch" model in the same US/European biotech ecosystem that Qiming US targets.
• OrbiMed: One of the largest dedicated healthcare investment firms globally; competes for the same therapeutics and digital health deals across stages with comparable sector specialization.
• RA Capital Management: Healthcare-focused crossover and early-stage investor with active participation in biotech Series A/B rounds similar to Qiming US's recent investments in Immutrin and Tenpoint Therapeutics.
• Arch Venture Partners: Long-tenured US biotech specialist backing transformative therapeutics and platform technologies; directly comparable investment thesis and US-based early-stage focus.
• Flagship Pioneering: Biotech platform-creation specialist operating in the same healthcare vertical with comparable conviction-driven early-stage investing and company-building approach.
• Foresite Capital: Healthcare-dedicated investment firm with comparable stage flexibility across therapeutics and digital health, targeting US-centric opportunities similar to Qiming US.
• 5AM Ventures: Early-stage healthcare specialist with similar Therapeutics and Digital Health vertical structure, comparable check sizes, and overlapping US biotech deal sourcing.

Broad incumbents

• New Enterprise Associates (NEA): Large multi-stage generalist VC with a sizable healthcare practice; competes for healthcare deals but as part of a much broader technology and bio portfolio rather than as a sector specialist.
• Andreessen Horowitz (a16z Bio): Generalist VC that launched a dedicated bio+health fund; overlaps in digital health and tech-enabled therapeutics but competes from a much broader firm-wide platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/qimingus
• LinkedInlinkedin.com/company/qiming-venture-partners-usa

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments44 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Qiming Venture Partners USA